Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Venetoclax Monotherapy in Japanese Subjects With Relapsed or Refractory Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
Conditions
Interventions
Venetoclax
Locations
7
Japan
Nagoya City University Hospital /ID# 277580
Nagoya, Aichi-ken, Japan
University of Fukui Hospital /ID# 279173
Yoshida-gun, Fukui, Japan
Gunma University Hospital /ID# 277576
Maebashi, Gunma, Japan
NHO Mito Medical Center /ID# 279175
Higashiibaraki-gun, Ibaraki, Japan
The University of Tokyo Hospital /ID# 279174
Bunkyo-ku, Tokyo, Japan
National Cancer Center Hospital /ID# 279076
Chuo-Ku, Tokyo, Japan
Start Date
March 17, 2026
Primary Completion Date
July 1, 2028
Completion Date
July 1, 2028
Last Updated
April 13, 2026
NCT06510491
NCT01804686
NCT04195633
NCT02269592
NCT05602363
NCT07231952
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions